Breaking News Instant updates and real-time market news.

AMGN

Amgen

$203.92

1.98 (0.98%)

09:04
01/22/19
01/22
09:04
01/22/19
09:04

Amgen: EC approves expanded indication for BLINCYTO monotherapy

Amgen announced that the European Commission has approved an expanded indication for BLINCYTO monotherapy to include adult patients with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal to 0.1% The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive ALL ever conducted. BLINCYTO, a bispecific CD19-directed CD3 T cell engager, is the first BiTE immunotherapy to receive regulatory approval globally.

  • 28

    Jan

AMGN Amgen
$203.92

1.98 (0.98%)

11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
12/18/18
HCWC
12/18/18
DOWNGRADE
HCWC
Neutral
Advaxis downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Advaxis (ADXS) to Neutral without a price target. Amgen's (AMGN) termination of a development and collaboration agreement puts ADXS-NEO in limbo, Ramakanth tells investors in a research note. The analyst believes Amgen's withdrawal has "considerably increased" the development risk on ADXS-NEO and potentially ADXS-HOT as well. He steps to the sidelines "until the viability of the programs can be assured."
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."

TODAY'S FREE FLY STORIES

FOX

21st Century Fox

$51.06

-0.64 (-1.24%)

, FOXA

21st Century Fox

$51.38

-0.57 (-1.10%)

17:26
03/18/19
03/18
17:26
03/18/19
17:26
Hot Stocks
Fox, Disney announces distribution adjustment multiple for acquisition »

Twenty-First Century Fox…

FOX

21st Century Fox

$51.06

-0.64 (-1.24%)

FOXA

21st Century Fox

$51.38

-0.57 (-1.10%)

DIS

Disney

$113.07

-1.89 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

XYF

X Financial

$6.23

0.715 (12.98%)

17:23
03/18/19
03/18
17:23
03/18/19
17:23
Earnings
X Financial reports Q4 EPS 24c, two estimates 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

CADE

Cadence Bancorp

$20.24

0.51 (2.58%)

17:22
03/18/19
03/18
17:22
03/18/19
17:22
Hot Stocks
Cadence Bancorp President Samuel Tortorici buys almost $1M in company shares »

Cadence Bancorp President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

CELP

Cypress Energy

$7.41

0.06 (0.82%)

17:22
03/18/19
03/18
17:22
03/18/19
17:22
Syndicate
Breaking Syndicate news story on Cypress Energy »

Cypress Energy files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

JWN

Nordstrom

$44.21

0.465 (1.06%)

17:21
03/18/19
03/18
17:21
03/18/19
17:21
Syndicate
Breaking Syndicate news story on Nordstrom »

Nordstrom files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$171.73

2.13 (1.26%)

17:20
03/18/19
03/18
17:20
03/18/19
17:20
Hot Stocks
General Dynamics awarded $2.04B Navy submarine material contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

FFIN

First Financial

$61.60

0.44 (0.72%)

, MBFI

MB Financial

$47.20

0.63 (1.35%)

17:19
03/18/19
03/18
17:19
03/18/19
17:19
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

First Financial…

FFIN

First Financial

$61.60

0.44 (0.72%)

MBFI

MB Financial

$47.20

0.63 (1.35%)

FOE

Ferro

$18.88

0.125 (0.67%)

FITB

Fifth Third

$28.74

0.42 (1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 16

    Apr

  • 23

    Apr

  • 23

    Apr

FOE

Ferro

$18.88

0.125 (0.67%)

, FFIN

First Financial

$61.60

0.44 (0.72%)

17:17
03/18/19
03/18
17:17
03/18/19
17:17
Hot Stocks
Breaking Hot Stocks news story on Ferro, First Financial »

Ferro to replace First…

FOE

Ferro

$18.88

0.125 (0.67%)

FFIN

First Financial

$61.60

0.44 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

FFIN

First Financial

$61.60

0.44 (0.72%)

, MBFI

MB Financial

$47.20

0.63 (1.35%)

17:17
03/18/19
03/18
17:17
03/18/19
17:17
Hot Stocks
First Financial to replace MB Financial in S&P 400 at open on 3/22 »

Fifth Third Bancorp…

FFIN

First Financial

$61.60

0.44 (0.72%)

MBFI

MB Financial

$47.20

0.63 (1.35%)

FITB

Fifth Third

$28.74

0.42 (1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 16

    Apr

  • 23

    Apr

  • 23

    Apr

CUTR

Cutera

$18.00

-0.29 (-1.59%)

17:13
03/18/19
03/18
17:13
03/18/19
17:13
Hot Stocks
Cutera director Daniel Plants buys almost $1.5M in company shares »

Cutera director Daniel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

SMTX

SMTC Corp.

$4.41

-0.1 (-2.22%)

17:13
03/18/19
03/18
17:13
03/18/19
17:13
Syndicate
Breaking Syndicate news story on SMTC Corp. »

SMTC Corp. files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 28

    May

SNE

Sony

$46.10

-0.16 (-0.35%)

, AAPL

Apple

$188.03

1.83 (0.98%)

17:09
03/18/19
03/18
17:09
03/18/19
17:09
Periodicals
PlayStation Vue now lets Apple TV users watch four channels at once, Verge says »

According to the…

SNE

Sony

$46.10

-0.16 (-0.35%)

AAPL

Apple

$188.03

1.83 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRRM

Verra Mobility

$10.89

0.15 (1.40%)

17:08
03/18/19
03/18
17:08
03/18/19
17:08
Earnings
Verra Mobility reports Q4 net ($38.0M) vs. ($29.2M) last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

EQH

AXA Equitable

$20.86

0.09 (0.43%)

17:06
03/18/19
03/18
17:06
03/18/19
17:06
Syndicate
AXA Equitable files to sell 40M shares of common stock for holders »

In connection with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$113.07

-1.89 (-1.64%)

17:04
03/18/19
03/18
17:04
03/18/19
17:04
Hot Stocks
ESPN+ to become exclusive distributor of UFC Pay-Per-View events »

UFC and ESPN+ announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

STML

Stemline

$12.92

-0.71 (-5.21%)

17:02
03/18/19
03/18
17:02
03/18/19
17:02
Recommendations
Stemline analyst commentary at Piper Jaffray »

Stemline sees positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REV

Revlon

$19.39

0.42 (2.21%)

17:02
03/18/19
03/18
17:02
03/18/19
17:02
Hot Stocks
Revlon down 15% after Q4 results miss estimates »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

ATR

AptarGroup

$103.69

0.75 (0.73%)

17:01
03/18/19
03/18
17:01
03/18/19
17:01
Hot Stocks
AptarGroup's Bidose approved by FDA for breakthrough treatment of depression »

Aptar Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

XELA

Exela Technologies

$3.82

-0.03 (-0.78%)

16:57
03/18/19
03/18
16:57
03/18/19
16:57
Earnings
Exela Technologies sees FY19 revenue $1.66B-$1.7B, consensus $1.68B »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

XELA

Exela Technologies

$3.82

-0.03 (-0.78%)

16:56
03/18/19
03/18
16:56
03/18/19
16:56
Earnings
Exela Technologies reports Q4 revenue $399.6M, consensus $401.4M »

Reports Q4 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

BIO

Bio-Rad

$313.64

3.58 (1.15%)

16:55
03/18/19
03/18
16:55
03/18/19
16:55
Hot Stocks
Bio-Rad extends 10-K filing by 15 days to complete year-end procedures »

In a regulatory 8-K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$47.09

0.09 (0.19%)

16:55
03/18/19
03/18
16:55
03/18/19
16:55
Conference/Events
Aerie Pharmaceuticals management to meet with JMP Securities »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

  • 08

    Apr

NOMD

Nomad Foods

$21.45

-0.07 (-0.33%)

16:54
03/18/19
03/18
16:54
03/18/19
16:54
Syndicate
Nomad Foods files to sell 20M ordinary shares »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIS

FIS

$108.14

-0.73 (-0.67%)

, WP

Worldpay

$108.52

9.8 (9.93%)

16:54
03/18/19
03/18
16:54
03/18/19
16:54
Conference/Events
FIS management to meet with Wolfe Research »

Senior Payments & IT…

FIS

FIS

$108.14

-0.73 (-0.67%)

WP

Worldpay

$108.52

9.8 (9.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 04

    Apr

ORN

Orion Group

$4.23

0.145 (3.55%)

16:52
03/18/19
03/18
16:52
03/18/19
16:52
Hot Stocks
Orion Group delays filing of Form 10-K »

Orion Group Holdings said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.